In the retail (i.e. non-hospital) segment, all of NVS/MNTA’s market share derives from the automatic substitution feature of US generic drugs. The retail segment is ~30% of the US Lovenox market by Rx volume and ~40% of the US Lovenox market by dollar sales.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.